Pfizer Stock News

Pfizer (NYSE:PFE) is one of the world's largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years.

Typically, investors put a focus on high-yield securities if the goal is to live off from portfolio income streams. These high-yielding securities come from BDC, REIT, MLP, CEF and other value-oriented segments. The common drawback of them is the lack of meaningful income growth and tightly correlated exposures.

Earnings season saw strong reports from Microsoft, Apple, Meta, and Amazon, boosting the S&P 500 by 2.75% and the Nasdaq by 2.82%. The Dividend Harvesting Portfolio gained 1.98% this week, with a total return of 23.42% and forward dividend income reaching $2,195.04. Added to positions in Bristol-Myers Squibb, Pfizer, and BP, focusing on undervalued stocks with strong dividend yields and growth ...

The average stock on the S&P 500 yields just 1.4%. If you invested $54,000 into stocks averaging that kind of a yield, you'd collect just $756 in annual dividend income.

These three companies have a dividend yield higher than 5%. Not only are these solid business, but they have raised dividends for many years and offer capital appreciation.

In this article, I present 10 attractive high-yield investment options for this month of May 2025, which not only offer dividend income but also potential for dividend growth. The selection process involves analyzing financial ratios, competitive advantages, valuations, and diversification across industries and countries to minimize risks and maximize returns. Highlighted top picks for May 2025...

Pharmaceutical imports to the U.S. surged in March as drugmakers stocked up ahead of potential U.S. tariffs on their products, which have historically been exempt from such fees.

What makes Pfizer and Altria alike? They have trouble keeping their customers. Altria's dividend yield is 7%, even as it trades at 11 times estimated earnings over the next 12 months – a 40% premium to Pfizer. Pfizer, meanwhile, continues to provide life-saving treatments, while its dealmaking at least offers hope of future breakthroughs.